As people age they become increasingly susceptible to chronic and extremely debilitating
brain diseases. The precise cause of the neuronal degeneration underlying these disorders …

After years of failed attempts to develop a disease-modifying therapy for Alzheimer's
disease, consistent evidence in support of clinical efficacy was finally presented for a …

The pathological processes leading to synapse loss, neuronal loss, brain atrophy and
gliosis in Alzheimer's disease (AD) and their relation to vascular disease and immunological …

This multicenter study examined 18F-FDG PET measures in the differential diagnosis of
Alzheimer's disease (AD), frontotemporal dementia (FTD), and dementia with Lewy bodies …

Objective Although the clinical course of Alzheimer disease (AD) is gradual, it is useful for a
number of reasons to distinguish between different levels of severity. The Clinical Dementia …

Background Frontotemporal dementia (FTD) is a complex disorder characterised by a broad
range of clinical manifestations, differential pathological signatures, and genetic variability …

Introduction Progress in understanding and management of vascular cognitive impairment
(VCI) has been hampered by lack of consensus on diagnosis, reflecting the use of multiple …

We assessed the geographical distribution of C9orf72 G 4 C 2 expansions in a pan‐E
uropean frontotemporal lobar degeneration (FTLD) cohort (n= 1,205), ascertained by the E …

Neurochemical dementia diagnostics (NDD) can significantly improve the clinically based
categorization of patients with early dementia disorders, and the cerebrospinal fluid (CSF) …

Objective: To examine the influence of the APOE genotype on levels of β-amyloid (Aβ)
plaque load and atrophy in patients with Alzheimer disease (AD) in vivo. Methods: Thirty-two …